SEC Comment Letter 0000000000-25-002463 to Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc.
Date: March 5, 2025 · CIK: 0001658551 · Accession: 0000000000-25-002463
AI Filing Summary & Sentiment
File numbers found in text: 333-285525
Letter
March 5, 2025 Joshua B. Cohen Co-Chief Executive Officer Amylyx Pharmaceuticals, Inc. 43 Thorndike St. Cambridge, Massachusetts 02141 Justin B. Klee Co-Chief Executive Officer Amylyx Pharmaceuticals, Inc. 43 Thorndike St. Cambridge, Massachusetts 02141 Re:Amylyx Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 4, 2025 File No. 333-285525 Dear Joshua B. Cohen and Justin B. Klee: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Marishka DeToy, Esq.
Show Raw Text
March 5, 2025
Joshua B. Cohen
Co-Chief Executive Officer
Amylyx Pharmaceuticals, Inc.
43 Thorndike St.
Cambridge, Massachusetts 02141
Justin B. Klee
Co-Chief Executive Officer
Amylyx Pharmaceuticals, Inc.
43 Thorndike St.
Cambridge, Massachusetts 02141
Re:Amylyx Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed March 4, 2025
File No. 333-285525
Dear Joshua B. Cohen and Justin B. Klee:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Marishka DeToy, Esq.